GlaxoSmithKline Spotlights Immune System And Oncology R&D

Two-Year Effort To Refocus Research Pipeline Bearing Fruit

New oncology and immunology products are moving rapidly through GSK’s refocused research pipeline, including new agents for multiple myeloma, endometrial and head and neck cancer, adding to efforts against COVID-19, respiratory syncytial virus infection and HIV/AIDS.  

Lab_Glassware
• Source: Shutterstock

GlaxoSmithKline plc’s latest addition to its immuno-oncology clinical portfolio is an anti-CD96 antibody, GSK6097608, developed in its collaboration with 23andMe, Inc.., which has just entered Phase I studies, according to the company’s chief scientific officer Hal Barron.

CD96 is an immune checkpoint protein expressed on T cells and NK cells, and blocking its effect, a new mechanism-of-action,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer